

Editorial

These are exciting times for research in the field of neuromuscular diseases. In recent years we have seen great progress in understanding the genetic, genomic, molecular and physiologic underpinnings of many neuromuscular disorders, leading to the first clinical trials based on molecular and genetic mechanisms of disease. It is clear that the most promising times for translational research in these diseases lie yet ahead.

Such a wealth of innovative research deserves a dedicated high quality forum. As Editors-in-Chief, we are thus delighted to announce the launch of the Journal of Neuromuscular Diseases (JND), a new journal to cover this evolving translational space by giving equal weight to basic science, pre-clinical and clinical studies in neuromuscular diseases and related disorders (including research relevant to the muscular dystrophies, myopathies, myasthenic syndromes and myasthenia gravis, spinal muscular atrophy, neuropathies, myotonias and myositis and related disorders).

Most importantly we would like to thank our distinguished Associate Editors and our outstanding international Editorial Board (<http://www.iospress.nl/journal-of-neuromuscular-diseases/?tab=editorial-board>) who have generously given their support to the JND. The participation of so many of the world's best scientists in the field constitutes the best basis to guarantee the success of the journal.

We are delighted to see that the launch issue (<http://iospress.metapress.com/content/122899/>) already features an impressive line-up of research articles and reviews. In addition, JND will publish commentaries, short communications, and letters-to-the-editor. All articles will be published online rapidly after acceptance and also in print. The journal also offers an affordable open access option and will be freely accessible for 2014.

We are confident that JND will serve our community well and will be a trusted forum for advancing the frontiers of translational research in our field in the coming years and decades.

Editor-in-Chief

Carsten G. Bönnemann
National Institute of Neurological Disorders and
Stroke/NIH, Bethesda, MD, USA
E-mail: carsten.bonnemann@nih.gov

Editor-in-Chief

Hanns Lochmüller
Institute of Genetic Medicine Newcastle University,
Newcastle upon Tyne, UK
E-mail: hanns.lochmuller@ncl.ac.uk